Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma

Combination anti-PD-(L)1/CTLA-4 blockade is approved in patients with hepatocellular carcinoma (HCC) in the first-line setting or after sorafenib, but whether this treatment has efficacy after prior anti-PD-(L)1 therapy is unknown. We performed a multicenter retrospective review of patients with adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Alden, Stephanie L., Lim, Mir, Kao, Chester, Shu, Daniel, Singal, Amit G., Noonan, Anne, Griffith, Paige, Baretti, Marina, Ho, Won Jin, Kamel, Ihab, Yarchoan, Mark, Hsiehchen, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356567/
https://www.ncbi.nlm.nih.gov/pubmed/37484200
http://dx.doi.org/10.1158/2767-9764.CRC-23-0072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356567/
https://www.ncbi.nlm.nih.gov/pubmed/37484200
http://dx.doi.org/10.1158/2767-9764.CRC-23-0072

Ejemplares similares